HomeCompareNVYTF vs MRK

NVYTF vs MRK: Dividend Comparison 2026

NVYTF yields 416.67% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVYTF wins by $15446.80M in total portfolio value
10 years
NVYTF
NVYTF
● Live price
416.67%
Share price
$0.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15446.85M
Annual income
$10,492,957,272.45
Full NVYTF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NVYTF vs MRK

📍 NVYTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVYTFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVYTF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVYTF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVYTF
Annual income on $10K today (after 15% tax)
$35,416.67/yr
After 10yr DRIP, annual income (after tax)
$8,919,013,681.58/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, NVYTF beats the other by $8,919,005,353.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVYTF + MRK for your $10,000?

NVYTF: 50%MRK: 50%
100% MRK50/50100% NVYTF
Portfolio after 10yr
$7723.46M
Annual income
$5,246,483,535.29/yr
Blended yield
67.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NVYTF
No analyst data
Altman Z
-0.6
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVYTF buys
0
MRK buys
0
No recent congressional trades found for NVYTF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVYTFMRK
Forward yield416.67%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$15446.85M$56.8K
Annual income after 10y$10,492,957,272.45$9,798.13
Total dividends collected$14996.03M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NVYTF vs MRK ($10,000, DRIP)

YearNVYTF PortfolioNVYTF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$52,367$41,666.67$11,206$366.19+$41.2KNVYTF
2$259,952$203,920.04$12,650$502.35+$247.3KNVYTF
3$1,224,201$946,051.97$14,407$694.19+$1.21MNVYTF
4$5,473,698$4,163,802.84$16,585$967.82+$5.46MNVYTF
5$23,256,265$17,399,408.07$19,342$1,363.89+$23.24MNVYTF
6$93,973,351$69,089,147.58$22,913$1,947.19+$93.95MNVYTF
7$361,461,534$260,910,048.59$27,662$2,823.89+$361.43MNVYTF
8$1,324,680,829$937,916,987.81$34,159$4,173.35+$1324.65MNVYTF
9$4,629,809,751$3,212,401,263.77$43,337$6,308.80+$4629.77MNVYTF
10$15,446,853,706$10,492,957,272.45$56,776$9,798.13+$15446.80MNVYTF

NVYTF vs MRK: Complete Analysis 2026

NVYTFStock

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

Full NVYTF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NVYTF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVYTF vs SCHDNVYTF vs JEPINVYTF vs ONVYTF vs KONVYTF vs MAINNVYTF vs JNJNVYTF vs ABBVNVYTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.